The Dynamic Use of <i>EGFR</i> Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

<div>(a) Electropherogram of cfDNA samples using the High Sensitivity D1000 ScreenTape® (up) and Genomic DNA ScreenTape® (down). The upper 181 bp peak corresponds to the predominant cfDNA. (b) Comparison of the cfDNA concentrations obtained using the Roche and Thermo Fisher methods for cfDNA extraction from paired plasma samples.</div>

Disease Markers

fig1

Figure 1

Figure 1: The Dynamic Use of <i>EGFR</i> Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients 

Figure 1 | The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients 